Abstract: A physical therapy device comprising a bench, having a seating surface and legs and a pair of horizontal supports positioned to either side of the knees of a person seated on the bench, a quick release securing device connected to each of the pair of supports, a rail connected to one of the quick release securing devices, a body pivotally attached to said rail, a foot rest attached to said rail and the foot rest and rail arranged to rotate with respect to said body about a pivot axis, the body having an adjustment mechanism to adjust the amount of force required to rotate the rail with respect to the body, wherein said body is repositionable between first and second positions, to provide physical therapy to the knee.

Abstract: A physical therapy device comprising a bench, having a seating surface and legs and a pair of horizontal supports positioned to either side of the knees of a person seated on the bench, a quick release securing device connected to each of the pair of supports, a rail connected to one of the quick release securing devices, a body pivotally attached to said rail, a foot rest attached to said rail and the foot rest and rail arranged to rotate with respect to said body about a pivot axis, the body having an adjustment mechanism to adjust the amount of force required to rotate the rail with respect to the body, wherein said body is repositionable between first and second positions, to provide physical therapy to the knee.

Abstract: A physical therapy device comprising a frame; a body attachable to said frame; an arm attached to said body and arranged to rotate with respect to said body about a pivot axis. The body is repositionable between first and second orientations, in said second orientation said pivot axis oriented non-parallel to its position in said first orientation.

Abstract: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.

Abstract: The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.

Abstract: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.

Abstract: The present invention relates to novel nucleic acids encoding a mammalian WNK, and proteins encoded thereby, preferably, human WNK1 and human WNK4. These novel nucleic acids, and mutant forms thereof, are associated with, inter alia, renal electrolyte handling, hypertension, and pseudohypoaldosterism type II (PHA II). That is, the present invention relates to novel mutations (e.g., deletions and missense mutations in an exon, intron, or both, of a nucleic acid encoding a WNK) that mediate and/or are associated with altered expression, among other things. These mutations are, in turn, associated with and/or mediate disease (e.g., hypertension, PHA II, and the like). Thus, these nucleic acids provide a novel target for treatment, diagnosis, and development of therapeutics to treat these diseases.